| Glaxo plans to beat rivals in emerging markets |
|
| Thursday, December 10, 2009 |
  |
|
|
GlaxoSmithKline PLC said it plans to
outpace its rivals in the race to emerging markets as revenue from traditional
western pharmaceutical markets continues to slow, according to the Associated Press. At an investor briefing, Abbas
Hussein, London-based Glaxo's head of emerging markets, said that the company
will pursue acquisitions and alliances in the region. Hussein said that Glaxo
is focusing on a combined pool of branded generics, vaccines and traditional
patented medicines to beef up its exposure to emerging markets. Drug companies
are battling to win a large piece of the pie as they look for substitute
revenue in the face of increased competition for patented drugs in the United
States and Western Europe. Drug sales in emerging markets are expected to
double by 2015 from the current 50 billion pounds ($81 billion) thanks to a
number of factors including a high birth rate and a swiftly increasing middle
class. Glaxo expects operating margins in the region to remain at current
levels of around 35 percent of sales.
|
|
|
|
|
The series offers 29 displacements, with pressures to 500-PSI standard, some offering pressures up to 2,500 PSI.
